GlassScriptPhysician profile
Khang N Tran
NPI 1821031766
$4,615.77
in general payments reported to CMS, 2019-2025
25 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $273 · 2021: $775 · 2022: $1,726 · 2023: $992 · 2024: $65.49 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $422 · Gift: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $422.00 |
| Gift | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cepheid | $1,038.00 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $594.86 | 2021-2022 | |
| Abbott Laboratories | $512.03 | 2021-2023 | Freestyle Libre 3 |
| Celltrion, INC. | $350.00 | 2025 | Stoboclo |
| Novo Nordisk INC | $297.28 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $281.73 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Stryker Corporation | $183.33 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $172.94 | 2019-2021 | |
| Lilly USA, LLC | $165.95 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Eisai INC. | $163.37 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $133.44 | 2022 | |
| Abbvie INC. | $120.92 | 2021-2023 | Qulipta, Synthroid |
| Pfizer INC. | $119.02 | 2022-2025 | |
| Amgen INC. | $88.97 | 2021-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $77.28 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $76.16 | 2019 | |
| Genentech USA, INC. | $45.99 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.87 | 2023 | |
| Exact Sciences Corporation | $37.04 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $29.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.94 | 2020 | |
| Esperion Therapeutics, INC. | $20.89 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.34 | 2021 | |
| Adlon Therapeutics L.P. | $12.35 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khang Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.